相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacodynamic analysis of hypertension caused by lenvatinib using real-world postmarketing surveillance data
Yuki Otani et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2021)
Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors
Maddalena Centanni et al.
FRONTIERS IN PHARMACOLOGY (2020)
Model-based Dose Individualization of Sunitinib in Gastrointestinal Stromal Tumors
Maddalena Centanni et al.
CLINICAL CANCER RESEARCH (2020)
Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study
Yoshihiko Tomita et al.
BMC CANCER (2019)
Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor
Sarah Waliany et al.
JACC: CARDIOONCOLOGY (2019)
Individualized dosing with axitinib: rationale and practical guidance
Manuela Schmidinger et al.
FUTURE ONCOLOGY (2018)
Minimally sufficient numbers of measurements for validation of 24-hour blood pressure monitoring in chronic kidney disease
Rajiv Agarwal et al.
KIDNEY INTERNATIONAL (2018)
Understanding short-term blood-pressure-variability phenotypes: from concept to clinical practice
Veerendra Melagireppa Chadachan et al.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE (2018)
Understanding and applying pharmacometric modelling and simulation in clinical practice and research
Joseph F. Standing
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
Remy B. Verheijen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring
Dhanusha Sabanathan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients
E. Schindler et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014)
F. T. Musuamba et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
White-Coat Effect Among Older Adults: Data From the Jackson Heart Study
Rikki M. Tanner et al.
JOURNAL OF CLINICAL HYPERTENSION (2016)
Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia
Gloria Ravegnini et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review
Meta H. M. Diekstra et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2016)
Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma
B. I. Rini et al.
ANNALS OF ONCOLOGY (2015)
Population Pharmacokinetic-Pharmacodynamic Modelling of 24-h Diastolic Ambulatory Blood Pressure Changes Mediated by Axitinib in Patients with Metastatic Renal Cell Carcinoma
Ying Chen et al.
CLINICAL PHARMACOKINETICS (2015)
Does home blood pressure monitoring improve patient outcomes? A systematic review comparing home and ambulatory blood pressure monitoring on blood pressure control and patient outcomes
Tonya L. Breaux-Shropshire et al.
INTEGRATED BLOOD PRESSURE CONTROL (2015)
Population pharmacokinetic analysis of axitinib in healthy volunteers
May Garrett et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets
Huixin Yu et al.
CLINICAL PHARMACOKINETICS (2014)
Sorafenib Dose Escalation Is Not Uniformly Associated With Blood Pressure Elevations in Normotensive Patients With Advanced Malignancies
S. Karovic et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Nonlinear Mixed Effects Modeling of the Diurnal Blood Pressure Profile in a Multiracial Population
Petra C. van Rijn-Bikker et al.
AMERICAN JOURNAL OF HYPERTENSION (2013)
Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis
Brian I. Rini et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial
Brian I. Rini et al.
LANCET ONCOLOGY (2013)
More Sound Cancer Therapy Biomarker Development With Active Noise Control
Michael L. Maitland
ONCOLOGIST (2013)
PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST
E. K. Hansson et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST
E. K. Hansson et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
Standard Error of Empirical Bayes Estimate in NONMEM® VI
Dongwoo Kang et al.
KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY (2012)
Home Blood Pressure Monitoring in the Diagnosis and Treatment of Hypertension: A Systematic Review
George S. Stergiou et al.
AMERICAN JOURNAL OF HYPERTENSION (2011)
Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
Brian I. Rini et al.
CLINICAL CANCER RESEARCH (2011)
Pharmacokinetic/Pharmacodynamic Modeling of Biomarker Response to Sunitinib in Healthy Volunteers
A. Lindauer et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels
Mariette H. W. Kappers et al.
HYPERTENSION (2010)
Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid Tumors
Marlies H. G. Langenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Call to Action on Use and Reimbursement for Home Blood Pressure Monitoring: Executive Summary A Joint Scientific Statement From the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association
Thomas G. Pickering et al.
HYPERTENSION (2008)
Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure
L Brynne et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Comparison of manual versus ambulatory blood pressure measurements with pharmacokinetic-pharmacodynamic modeling of antihypertensive compounds:: Application to moxonidine
IF Trocóniz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
分享论文
